Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 17, 2024, we reported on a study presented at IDWeek 2024 that examined the association between social vulnerability, race, and influenza, COVID-19, and respiratory syncytial virus (RSV) vaccine uptake in the US.
The study
Researchers analyzed data from 341 029 patients who were diagnosed with acute respiratory infections at University Hospitals of Cleveland between October 2023 and April 2024. Patient demographics and vaccination statuses were collected from health records and matched with data from the US CDC’s Social Vulnerability Index (SVI). Researchers then geocoded and segmented the data into quartiles, with Q5 being the highest SVI category and Q1 being the lowest.
Among the cohort, 60% were women and 81% were White, according to investigators. Black individuals were overrepresented among individuals in SVI Q4 at 37% and underrepresented among the least vulnerable population (ie, Q1) at 3.2%, despite making up 14% of the study’s population.
The findings
Vaccine uptake among all participants regardless of SVI quartile and race was 37% for influenza, 14% for SARS-CoV-2, and 8.8% for RSV. Vaccination rates decreased, however, as the SVI quartile increased, particularly among Black participants.
After investigators adjusted for age, sex, and race, they found that the odds of receiving an influenza vaccine were lower for Black individuals compared to White individuals in all SVI quartiles, with the greatest disparity in SVI Q5 (Black: prevalence ratio [PR] 0.59, 95% CI 0.57-0.61; White: PR 0.72, 95% CI 0.70-0.75). Similarly, they also reported that the odds of receiving a SARS-CoV-2 vaccine and RSV vaccine were lower for Black individuals compared to White individuals across all SVI quartiles.
Authors' comment
"Even when controlling for demographic factors, household income, health insurance coverage and geographic location, the study’s findings maintain that neighborhood factors and race are significantly associated with vaccination status against common respiratory viruses. Disparities this vast are not to be overlooked — they require multifaceted interventions that meet people where they are socially and increase access to essential preventive measures.”
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 17, 2024, we reported on a study presented at IDWeek 2024 that examined the association between social vulnerability, race, and influenza, COVID-19, and respiratory syncytial virus (RSV) vaccine uptake in the US.
The study
Researchers analyzed data from 341 029 patients who were diagnosed with acute respiratory infections at University Hospitals of Cleveland between October 2023 and April 2024. Patient demographics and vaccination statuses were collected from health records and matched with data from the US CDC’s Social Vulnerability Index (SVI). Researchers then geocoded and segmented the data into quartiles, with Q5 being the highest SVI category and Q1 being the lowest.
Among the cohort, 60% were women and 81% were White, according to investigators. Black individuals were overrepresented among individuals in SVI Q4 at 37% and underrepresented among the least vulnerable population (ie, Q1) at 3.2%, despite making up 14% of the study’s population.
The findings
Vaccine uptake among all participants regardless of SVI quartile and race was 37% for influenza, 14% for SARS-CoV-2, and 8.8% for RSV. Vaccination rates decreased, however, as the SVI quartile increased, particularly among Black participants.
After investigators adjusted for age, sex, and race, they found that the odds of receiving an influenza vaccine were lower for Black individuals compared to White individuals in all SVI quartiles, with the greatest disparity in SVI Q5 (Black: prevalence ratio [PR] 0.59, 95% CI 0.57-0.61; White: PR 0.72, 95% CI 0.70-0.75). Similarly, they also reported that the odds of receiving a SARS-CoV-2 vaccine and RSV vaccine were lower for Black individuals compared to White individuals across all SVI quartiles.
Authors' comment
"Even when controlling for demographic factors, household income, health insurance coverage and geographic location, the study’s findings maintain that neighborhood factors and race are significantly associated with vaccination status against common respiratory viruses. Disparities this vast are not to be overlooked — they require multifaceted interventions that meet people where they are socially and increase access to essential preventive measures.”
Click here for more details.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Digital Asthma Self Management Program Improves Symptom Control But Disparities in Benefit Are Clear
A smartphone-based asthma management program significantly enhanced symptom control, but may require engagement or cultural tailoring to expand the effect.
Primary Viewpoints: Immunizations with Dr Steven P. Furr
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.
FDA to Review GSK's Application for Expanded Use of RSV Vaccine in High-Risk Adults Aged 18 to 49
GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years
Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.
Clinic- and System-Level Factors Drive Racial Disparities in COVID-19 Antiviral Prescribing, Study Finds
A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.
Digital Asthma Self Management Program Improves Symptom Control But Disparities in Benefit Are Clear
A smartphone-based asthma management program significantly enhanced symptom control, but may require engagement or cultural tailoring to expand the effect.
Primary Viewpoints: Immunizations with Dr Steven P. Furr
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.
FDA to Review GSK's Application for Expanded Use of RSV Vaccine in High-Risk Adults Aged 18 to 49
GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
FDA Grants Full Approval of Moderna’s COVID-19 Vaccine for High-Risk Children Aged 6 Months to 11 Years
Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.
Clinic- and System-Level Factors Drive Racial Disparities in COVID-19 Antiviral Prescribing, Study Finds
A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.